Download the ESMO 2012 Abstract Book - Oxford Journals

Annals of Oncology subject index
polymorphism, ix183 (536P), ix208 (613P), ix216
(640)
polymorphisms, ix352 (1078P), ix185 (544P),
ix281 (850P)
pontine glioma, ix145 (413PD)
pooled analysis, ix273 (825P)
poor PS, ix421 (1282P), ix433 (1323)
poorly differentiated carcinoma, ix89 (225P)
population-based programme, ix53 (88IN)
population-based study, ix53 (89IN)
port central venous catheters, ix522 (1626)
positive predictive value, ix373 (1146)
positron emission tomography (PET), ix480
(1482PD)
post-induction therapy, ix419 (1278P)
post-marketing surveillance, ix505 (1566P)
post-marketing, ix504 (1563P)
post-PD, ix482 (1490P)
postoperative radiation, ix226 (674P)
postoperative radiotherapy, ix216 (639)
power doppler, ix134 (379)
ppar, ix201 (590P)
PRAME antigen, ix361 (1110O), ix386 (1182P)
pre-menopausal cancer patients, ix501 (1551PD)
pre-operative chemoradiotherapy, ix197 (575P),
ix207 (610P)
pre-operative staging, ix384 (1177P)
preclinical model, ix337 (1027P)
preclinical models, ix61 (120IN)
preclinical, ix537 (1675P)
prediction of response, ix504 (1561P), ix282
(852P)
predictive biomarker, ix84 (204P), ix107 (289P)
predictive biomarkers, ix180 (525PD), ix197
(575P), ix275 (833P)
predictive factors, ix407 (1241P), ix429 (1306P),
ix218 (647)
predictive impact, ix182 (532P)
predictive marker, ix74 (172O), ix265 (803P)
predictive markers, ix364 (1117PD)
predictive role, ix216 (640)
predictive significance, ix381 (1170P)
predictive/ prognostic value, ix431 (1314)
predictors factors, ix276 (835P)
prednisone, ix302 (918P)
preeclampsia, ix454 (1394P)
preference, ix293 (892TiP)
pregnancy, ix355 (1090P), ix133 (373P)
preoperative chemotherapy, ix130 (362P)
preoperative concomitant chemoradiotherapy,
ix89 (224P)
preoperative radiochemotherapy, ix208 (1704P),
ix545 (1704P)
preoperative radiotherapy, ix216 (639)
preoperative treatment, ix197 (578P)
pretreated patients, ix325 (986P)
prevalence, ix298 (902P), ix213 (632)
prevention, ix473 (1461), ix477 (1475), ix513
(1594P), ix173 (508)
prgnosis, ix119 (327PD)
primary cardiac sarcoma, ix489 (1513)
primary endocrine therapy, ix100 (263P)
primary lesion, ix276 (834P)
primary mediastinal germ cell tumour, ix497
(1539P)
primary tumor, ix131 (368P), ix182 (531P)
procalcitonin, ix525 (1637)
progesteron reseptor, ix105 (279P)
progesterone receptor, ix104 (278P)
prognosis factors, ix94 (244)
prognosis, SIADH, small cell lung cancer (SCLC),
retrospective study, ix494 (1528P)
prognosis, ix348 (1062O), ix353 (1080P), ix365
(1120P), ix427 (1300P), ix516 (1603P), ix538
(1681P), ix541 (1688PD), ix83 (201P), ix100
(264P), ix110 (299), ix184 (539P), ix184 (540P),
ix201 (589P), ix208 (613P), ix217 (644), ix287
(868), ix53 (89IN)
prognostic biomarker, ix338 (1030P), ix350
(1071P), ix76 (178P), ix79 (187P), ix92 (233),
ix199 (582P), ix226 (675P), ix261 (791PD),
ix300 (911P)
prognostic factor, ix332 (1015), ix350 (1069PD),
ix387 (1186P), ix430 (1310P), ix496 (1533P),
ix73 (168O), ix145 (414PD), ix186 (547P), ix253
(771), ix265 (804P)
prognostic factors, ix332 (1012), ix357 (1097),
ix380 (1167P), ix387 (1184P), ix387 (1185P),
ix392 (1203P), ix441 (1351), ix485 (1498P),
ix497 (1537P), ix497 (1538P), ix497 (1540), ix79
(187P), ix99 (258P), ix107 (288P), ix132 (371P),
ix197 (577P), ix216 (641), ix262 (793PD), ix276
(836P), ix298 (903P), ix328 (999P)
prognostic marker, ix530 (1654P), ix74 (172O),
ix182 (533P)
prognostic model, ix299 (907P)
prognostic score, ix162 (469P), ix298 (903P)
prognostic significance, ix381 (1170P)
prognostic, ix338 (1031P), ix339 (1033P)
progression free survival, ix339 (1035P), ix392
(1203P), ix217 (645)
progression, survival, ix297 (901PD)
progression-free survival (PFS), ix331 (1011),
ix350 (1070PD), ix381 (1171P), ix453 (1391P),
ix526 (1643), ix119 (328PD), ix232 (694P),
ix260 (787O), ix273 (825P)
progression-free survival, ix449 (1378P), ix231
(690P)
proliferation, ix112 (305)
promoter methylation, ix186 (548P)
prophylactic cranial irradiation, ix394 (1207P)
prophylaxis, ix521 (1623)
prospective cohort, ix488 (1511P)
prostate cancer ibandronate y-27632 rho-kinase
inhibitor, ix312 (947)
prostate cancer screening, ix53 (87IN)
prostate cancer working group (PCWG)-2, ix297
(901PD)
prostate cancer, ix384 (1178TiP), ix538 (1680P),
ix89 (223P), ix38 (49IN), ix291 (884), ix294
(893O), ix295 (896O), ix297 (899PD), ix298
(902P), ix298 (904P), ix299 (906P), ix301
(914P), ix302 (916P), ix304 (922P), ix306
(928P), ix309 (937P), ix309 (938P), ix310
(939P), ix310 (941P), ix311 (942P), ix311
(944P), ix312 (945), ix313 (950), ix314 (952),
ix314 (953), ix314 (955), ix315 (957), ix315
(959), ix316 (961)
prostate tumor xenograft, ix312 (946)
prostate volume, ix306 (930P)
prostate-specific antigen (PSA), ix299 (907P)
prostate, ix39 (53IN)
prostvac, ix38 (46IN)
proteasome inhibitor, ix44 (66IN)
protein S, ix356 (1094)
protein tyrosine phosphatase non-receptor type 12
(PTPN 12), ix127 (353P)
protein-expression profiling, ix337 (1026P)
proteinuria, ix171 (499P)
proteomic biomaker, ix89 (224P), ix91 (232)
proteomics, ix407 (1241P)
prophylactic cranial irradiation, ix98 (256P)
PRRT, ix47 (75IN)
pruritus, ix500 (1550PD)
PSA response, ix313 (951)
PSA, mCRPC, ix310 (940P)
pseudomyxoma peritonei, ix254 (774)
PSF3, ix92 (233)
psycho-oncology, ix474 (1462PD), ix475 (1467P),
ix476 (1470P)
psycho-social outcomes, ix474 (1462PD), ix475
(1466P)
psychological distress, ix343 (1047P), ix517
(1606P)
psychometric properties of Patient Dignity
Inventory Italian version, ix516 (1601P)
psychometric properties, ix516 (1602P)
psychooncology, ix477 (1475)
PTCH1, ix365 (1121P)
PTEN, ix213 (630)
PTK7, ix184 (539P)
pulmonary adenocarcinoma, ix391 (1198P)
pulmonary embolism, ix444 (1360)
pulmonary neoplasm, ix383 (1174P)
Q
13q deletion, ix355 (1088P)
QOL, ix511 (1586P), ix232 (695P)
QTc, ix173 (507)
quality assurance, ix86 (213P)
quality of care indicators, ix457 (1405)
quality of care, ix457 (1403), ix458 (1407), ix53
(89IN)
quality of documentation, ix448 (1374P)
quality of life (QOL) assessment, ix512 (1590P),
ix141 (403), ix211 (623), ix314 (954)
quality of life (QoL), ix346 (1060), ix436 (1332),
ix512 (1589P), ix514 (1596P), ix515 (1600P),
ix120 (330P), ix120 (331P), ix145 (415PD),
ix237 (712P), ix261 (792PD), ix269 (815P)
quality of life, ix343 (1047P), ix459 (1413TiP),
ix474 (1463P), ix475 (1468P), ix121 (334P),
ix191 (561P), ix296 (898PD), ix315 (956), ix328
(998P)
quality-adjusted survival, ix192 (564P)
R
radiation therapy, ix148 (428P), ix200 (586P)
radiation-induced malignancy, ix343 (1048P)
radiation, ix69 (152P), ix537 (1676P), ix257
(782TiP)
radical mastectomy, ix131 (365P)
radical prostatectomy, ix299 (907P)
radical treatment, ix212 (626)
radiochemotherapy, ix37 (45IN)
radiographic progression-free survival, ix294
(894O)
radiopeptide therapy, ix379 (1162P)
radiosensitiser, ix42 (61IN)
radiosensitization, ix537 (1677P)
radiotherapy induced epiphyseal injury, ix526
(1642)
radiotherapy-induced epiphyseal injury, ix526
(1641)
radiotherapy-induced oral mucositis, ix346 (1059)
radiotherapy, ix329 (1003P), ix334 (1016O), ix343
(1048P), ix343 (1049P), ix391 (1199P), ix457
(1406), ix475 (1466P), ix496 (1536P), ix70
(156P), ix525 (1636), ix537 (1677P), ix31
(26IN), ix131 (365P), ix148 (427P), ix150 (433),
ix172 (503), ix206 (607P), ix207 (611P), ix208
(614P), ix242 (729P), ix265 (801P), ix265
(803P), ix291 (885)
Raf/MEK inhibitor, ix164 (475P)
raltitrexed, ix178 (519O)
ramucirumab, ix363 (1115PD), ix408 (1245P),
ix422 (1287P)
randomised phase II trial, ix378 (1161P)
randomized clinical trial, ix410 (1250P), ix450
(1380P)
randomized discontinuation trial, ix319 (966O)
randomized phase II trial, ix224 (666O), ix242
(730P), ix297 (900PD)
randomized phase III trial, ix211 (625)
randomized trial, ix145 (413PD)
Rapalogues, ix334 (1017O)
rare cancer, ix66 (140IN)
rare tumor, ix488 (1509P), ix110 (297P), ix327
(993P)
RAS, ix46 (69IN)
rash, ix426 (1298P), ix435 (1328), ix79 (189P),
ix192 (563P)
rat food intake, ix161 (465P)
rat model, ix526 (1641), ix526 (1642)
Volume 23 | Supplement 9 | September 2012 doi:10.1093/annonc/mds467 | ix597